Journal of Blood Disorders & Transfusion

Mark D. Minden

Publications

• Short Communication
  Association between Treatment Response and Potential Indicators of Efficacy and Safety in a Phase III Trial of Decitabine in Older Patients with Acute Myeloid Leukemia
  Author(s): Mark D. Minden, Christopher Arthur, Jiří Mayer, Mark M. Jones, Erhan Berrak and Hagop KantarjianMark D. Minden, Christopher Arthur, Jiří Mayer, Mark M. Jones, Erhan Berrak and Hagop Kantarjian
  
  Objective: In a phase III trial, 485 patients aged 65 years or older with newly diagnosed acute myeloid leukemia received decitabine (20 mg/m2 intravenously for 5 days) or treatment of choice (supportive care or cytarabine 20 mg/m2 subcutaneously for 10 days) every 4 weeks. This post hoc analysis investigated potential efficacy and safety indicators and treatment response. Methods: Transfusions, intravenous antibiotics, and dose modifications were tabulated for responders (morphologic complete remission, complete remission with incomplete blood count recovery, or partial response) and nonresponders. Results: Median overall survival was significantly greater for treatment responders than for nonresponders (17.4 months vs 4.3 months; P<0.0001). Nonresponders had more intravenous antibiotic use (P=0.024), dose modifications per cycle (P=0.016), and platelet or red bloo.. View More»
  DOI: 10.4172/2155-9864.1000251

  Abstract PDF